Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Taps SRL as India, Middle East Distributor

NEW YORK (GenomeWeb News) – New Delhi-based Super Religare Laboratories will distribute Rosetta Genomics’ three microRNA-based cancer tests in India, Saudi Arabia, Qatar, and United Arab Emirates, Rosetta said today.

SRL will send the samples from the four countries to Rosetta Genomics’ CLIA-certified lab in Philadelphia for analysis.

“Our unique technology, mainly the use of microRNAs as biomarkers, and their stability in formalin fixed paraffin embedded blocks, will enable us to easily receive samples from around the world, without the need for temperature-controlled shipments,” Ronen Tamir, Rosetta Genomics’ chief commercialization officer, said in a statement.

The agreement covers Rosetta Genomics’ miRview test line, including the miRview mets test to identify the primary tumor site in patients with cancer of unknown primary origin, the miRview squamous test for differentiating squamous from non-squamous small cell lung cancer, and the miRview meso test for differentiating mesothelioma from other carcinomas in the lung.

“The two companies have also discussed the possibility to expand their relationship into research and development projects,” SRL’s CEO, Sanjeev Chaudhry, said in a statement.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.